Crossref
NEOADJUVANT THERAPY IN INTRAHEPATIC CHOLANGIOCARCINOMA - A RISK-PROFILE STRATIFIED ANALYSIS
HPB · 2026 · 28 · S25-S26
DOI: 10.1016/j.hpb.2026.04.042 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2026. Verfasst von Y. Dong und 13 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Dong, Y., Podrascanin, V., Li, Z., Pereyra, D., Santol, J., Ammann, M., Fonkoua, L. K., Graham, R., Conboy, C., Tran, N., Warner, S., Nagorney, D., Smoot, R., & Starlinger, P. (2026). NEOADJUVANT THERAPY IN INTRAHEPATIC CHOLANGIOCARCINOMA - A RISK-PROFILE STRATIFIED ANALYSIS. HPB, 28, S25-S26. https://doi.org/10.1016/j.hpb.2026.04.042
Vancouver
Dong Y, Podrascanin V, Li Z, Pereyra D, Santol J, Ammann M, et al. NEOADJUVANT THERAPY IN INTRAHEPATIC CHOLANGIOCARCINOMA - A RISK-PROFILE STRATIFIED ANALYSIS. HPB. 2026;28:S25-S26. doi:10.1016/j.hpb.2026.04.042
BibTeX
@article{Dong2026,
author = {Dong, Y. and Podrascanin, V. and Li, Z. and Pereyra, D. and Santol, J. and Ammann, M. and Fonkoua, L. Kankeu and Graham, R. and Conboy, C. and Tran, N. and Warner, S and Nagorney, D. and Smoot, R. and Starlinger, P.},
title = {NEOADJUVANT THERAPY IN INTRAHEPATIC CHOLANGIOCARCINOMA - A RISK-PROFILE STRATIFIED ANALYSIS},
journal = {HPB},
year = {2026},
volume = {28},
pages = {S25--S26},
doi = {10.1016/j.hpb.2026.04.042}
}
EUVIMED